Kelonia Therapeutics Acquired by Eli Lilly | Healthcare M&A Deal

Eli Lilly has acquired Kelonia Therapeutics, a healthcare services other business in the United States, for $7 billion. Kelonia Therapeutics is a gene therapy platform company focused on developing treatments for serious diseases, supporting Eli Lilly acquisitions in advanced biologics. Eli Lilly acquisitions in healthcare services other acquisition categories reflect a strategic acquisition of capabilities that can expand its pipeline and strengthen platform acquisition efforts. The healthcare M&A is structured as a platform acquisition and is classified as a strategic acquisition by a strategic buyer, with deal size reported at $7 billion and an announced status.